This is the first study to present a comprehensive real‐world investigation into the prophylactic use of long‐acting granulocyte‐colony stimulating factor (G‐CSF) for managing chemotherapy‐induced neutropenia in patients with gastrointestinal cancer. This evidence concerns the gene CSF3 and Decreased total neutrophil count.